

Resource Summary Report

Generated by SPARC SAWG on Jul 30, 2026

Alexa Fluor(R) 700 anti-mouse CD3

RRID:AB_493697

Type: Antibody

Proper Citation

BioLegend Cat# 100216, RRID:AB_493697

Antibody Information

URL: http://antibodyregistry.org/AB_493697

Proper Citation: BioLegend Cat# 100216, RRID:AB_493697

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Alexa Fluor(R) 700 anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_493697

Vendor: BioLegend

Catalog Number: 100216

Alternative Catalog Numbers: 100215

Record Creation Time: 20250819T231203+0000

Record Last Update: 20250820T043608+0000

Ratings and Alerts

No rating or validation information has been found for Alexa Fluor(R) 700 anti-mouse CD3.

No alerts have been found for Alexa Fluor(R) 700 anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 68 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Li K, et al. (2025) An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer. *Cell stem cell*, 32(8), 1218.

Gliniak CM, et al. (2025) FGF21 promotes longevity in diet-induced obesity through metabolic benefits independent of growth suppression. *Cell metabolism*, 37(7), 1547.

Muffels IJJ, et al. (2025) LIMK1 variants are associated with divergent endocrinological phenotypes and altered exocytosis dynamics. *iScience*, 28(6), 112585.

Dalangood S, et al. (2025) Cancer-associated adipocytes mediate CD8+T cell dysfunction via FGF21-driven lipolysis. *Cell reports*, 44(11), 116526.

Miranda-Waldetario MCG, et al. (2025) Long-lived IgE plasma cells that reside in the spleen contribute to the persistence of the IgE response. *Immunity*, 58(11), 2717.

Li H, et al. (2025) In Situ Delivery of Gasdermin E mRNA Promotes Antitumor Immunity via Creatine-Elicited Type I Interferon Signaling in Monocytes. *Cancer immunology research*, 13(6), 939.

Kim HC, et al. (2025) Gut microbiota dysbiosis induced by brain tumors modulates the efficacy of immunotherapy. *Cell reports*, 44(7), 115825.

Huai W, et al. (2025) OAS cross-activates RNase L intercellularly through cell-to-cell transfer of 2-5A to spread innate immunity. *Immunity*, 58(4), 797.

Oh JH, et al. (2025) Naturalized immune responses are stable over years in a colony of laboratory mice with wild-derived microbiota. *Immunity*, 58(9), 2305.

Wang R, et al. (2025) An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B γ 1/2 shedding. *Cell reports. Medicine*, 6(3), 101981.

Xu W, et al. (2025) NFE2-driven neutrophil polarization promotes pancreatic cancer liver metastasis progression. *Cell reports*, 44(2), 115226.

Caksa S, et al. (2025) Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4+ T Cells. *Cancer research*.

Mooser C, et al. (2025) Diet-derived LPS determines intestinal IgA induction and repertoire characteristics independently of the microbiota. *Immunity*, 58(7), 1778.

da Silva Bortoleti BT, et al. (2025) A monoclonal antibody that inhibits the shedding of CD16a and CD16b and promotes antibody-dependent cellular cytotoxicity against tumors. *Nature communications*, 16(1), 9915.

Ahn JJ, et al. (2025) Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity. *Cell reports. Medicine*, 6(8), 102257.

Wang C, et al. (2025) Gut microbe-derived metabolites drive psoriatic inflammation via modulation of skin Th17 cells. *Immunity*, 58(9), 2241.

Koliesnik I, et al. (2025) An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy. *Cell reports*, 45(1), 116757.

Hu C, et al. (2024) Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8⁺T cells. *Cell metabolism*, 36(3), 630.

Lin M, et al. (2024) Inflammatory dendritic cells restrain CD11b⁺CD4⁺ CTLs via CD200R in human NSCLC. *Cell reports*, 43(2), 113767.

Lim RJ, et al. (2024) CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer. *Cell reports. Medicine*, 5(4), 101479.